Journal articleCancer Invest · November 2021
Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobi ...
Full textLink to itemCite
Journal articleAm J Hematol · June 2020
Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown to improve clinical ...
Full textLink to itemCite
Journal articlePLoS One · 2020
Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic steatosis ...
Full textLink to itemCite
Journal articleInt J Radiat Oncol Biol Phys · September 1, 2019
PURPOSE: To evaluate the feasibility of reducing the dose of consolidation radiation therapy (RT) in diffuse large B-cell lymphoma. METHODS AND MATERIALS: This phase 2 study enrolled patients with diffuse large B-cell lymphoma, not otherwise specified and ...
Full textLink to itemCite
Journal articleClin Lymphoma Myeloma Leuk · October 2018
BACKGROUND: For patients with aggressive lymphomas who relapse after initial therapy, a durable response is rarely achieved with standard salvage therapies. Significant efforts have focused on the development of novel treatments with reduced toxicity. We c ...
Full textLink to itemCite
Journal articleLeuk Lymphoma · July 2015
We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All pa ...
Full textLink to itemCite
Journal articleInt J Radiat Oncol Biol Phys · May 1, 2015
PURPOSE: The German Hodgkin Study Group (GHSG) trial HD11 established 4 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and 30 Gy of radiation therapy (RT) as a standard for early stage (I, II), unfavorable Hodgkin lymphoma (HL). Addi ...
Full textLink to itemCite
Journal articleHematology Am Soc Hematol Educ Program · 2015
Peripheral T-cell lymphomas (PTCL), with the exception of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), have a very poor prognosis. Although current first line chemotherapy continues to be a CHOP-like (cyclophosphamide, d ...
Full textLink to itemCite
Journal articleOncology (Williston Park) · December 2014
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Approximately half of patients will present with advanced (stage III/IV) disease. The cornerstone of treatment is a combination of chemotherapy and immunotherapy, mos ...
Link to itemCite
Journal articleJ Clin Oncol · September 1, 2014
PURPOSE: Negative [(18)F]fluorodeoxyglucose (FDG) -positron emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy indicates a favorable prognosis in Hodgkin lymphoma (HL). We hypothesized that the negative predictive value wou ...
Full textLink to itemCite
Journal articleLeuk Lymphoma · December 2013
PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-dai ...
Full textLink to itemCite
Journal articleCancer Invest · March 2013
PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcadeâ„¢) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were ...
Full textLink to itemCite
Journal articleLeuk Res · January 2013
PURPOSE: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in dete ...
Full textLink to itemCite
Journal articleLeukemia · January 2013
Chronic lymphocytic leukemia (CLL) can be immunosuppressive in humans and mice, and CLL cells share multiple phenotypic markers with regulatory B cells that are competent to produce interleukin (IL)-10 (B10 cells). To identify functional links between CLL ...
Full textLink to itemCite
Journal articleOncology (Williston Park) · December 2012
Multiple randomized studies have demonstrated that chemotherapy, most commonly ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine), followed by consolidation radiation therapy is the most effective treatment program for early-stage Hodgkin ...
Link to itemCite
Journal articleInt J Radiat Oncol Biol Phys · November 1, 2012
PURPOSE: While consolidation radiation therapy (i.e., RT administered after chemotherapy) is routine treatment for patients with early-stage diffuse large B-cell lymphoma (DLBCL), the role of consolidation RT in stage III-IV DLBCL is controversial. METHODS ...
Full textLink to itemCite
Journal articleJournal of Geriatric Oncology · July 1, 2012
Objective: Older adults with acute myeloid leukemia (AML) tend to have worse complete remission (CR) rates and overall survival compared to their younger counterparts. At least one reason for this is increased expression of the multidrug resistance gene (M ...
Full textCite
Journal articleLeuk Lymphoma · February 2012
Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of TP53 gain-of-function mutants and to increas ...
Full textLink to itemCite
Journal articleOncology United States · January 1, 2012
Multiple randomized studies have demonstrated that chemotherapy, most commonly ABVD (doxorubicin [Adriamycin], bleomycin(Drug information on bleomycin), vinblastine(Drug information on vinblastine), dacarbazine(Drug information on dacarbazine)), followed b ...
Cite
Journal articleBlood · October 13, 2011
B-cell chronic lymphocytic leukemia (CLL), an incurable leukemia, is characterized by defective apoptosis. We found that the SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A) tumor suppressor, is overexpressed in primary CLL cells an ...
Full textLink to itemCite
Journal articleAnn Oncol · February 2011
BACKGROUND: 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography (PET) and gallium-67 citrate (gallium) response after chemotherapy are powerful prognostic factors in diffuse large B-cell lymphoma (DLBCL). However, clinical outcomes when co ...
Full textLink to itemCite
Journal articleClin Lymphoma Myeloma Leuk · December 2010
INTRODUCTION: We evaluated the complete remission (CR) rate in patients with acute myeloid leukemia (AML) in first relapse treated with fixed-dose-rate gemcitabine and mitoxantrone. In addition, we measured multidrug resistance (MDR) proteins on pretreatme ...
Full textLink to itemCite
Journal articleOncology (Williston Park) · November 30, 2010
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the United States. Historically, radiation therapy (RT) was the primary treatment for patients with localized disease. Several randomized trials have demonstrated t ...
Link to itemCite
Journal articleOncology (Williston Park, N.Y.) · November 30, 2010
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the United States. Historically, radiation therapy (RT) was the primary treatment for patients with localized disease. Several randomized trials have demonstrated t ...
Cite
Journal articleLeukemia · September 2010
B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell-cell interactions and soluble cytokines such as tumor necrosis factor (TNF). We evaluated the effect of ...
Full textLink to itemCite
Journal articleCancer Invest · July 2010
We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a h ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · January 2010
The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ...
Full textLink to itemCite
Journal articleClin Cancer Res · November 15, 2009
PURPOSE: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients. EXPERIME ...
Full textLink to itemCite
Journal articleClin Immunol · August 2009
T cell large granular lymphocyte leukemia (T-LGL) is a disease characterized by clonal expansion of cytotoxic T cells (CTLs). It generally follows an indolent course and is notable for an association with chronic inflammation, neutropenia and rheumatoid ar ...
Full textLink to itemCite
Journal articleCancer · July 1, 2009
BACKGROUND: Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed. METHODS: The median follow-up of survivors was 2.3 years. A total of 70 (73%) patients achieved a mor ...
Full textLink to itemCite
Journal articleLeukemia · December 2008
Survival of chronic lymphocytic leukemia (CLL) cells requires sustained activation of the antiapoptotic PI-3-K/Akt pathway, and many therapies for CLL cause leukemia cell death by triggering apoptosis. Blood lipoprotein particles are either pro- or antiapo ...
Full textLink to itemCite
Journal articleAm J Hematol · December 2007
Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgV(H)) mutation status, cytogenetic abnorma ...
Full textLink to itemCite
Journal articleClin Cancer Res · April 15, 2007
PURPOSE: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-re ...
Full textLink to itemCite
Journal articleAnn Hematol · May 2006
In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL ...
Full textLink to itemCite
Journal articleClin Cancer Res · December 1, 2005
PURPOSE: Fludarabine and cyclophosphamide is an effective combination but increases the risk of opportunistic infections due to depressed lymphocyte counts. In an attempt to preserve CD4 counts, we conducted a phase I, double-blind, placebo-controlled tria ...
Full textLink to itemCite
Journal articleBr J Haematol · March 2005
It is well known that the differentiation of acute promyelocytic leukaemia (APL) cells by all-trans-retinoic acid (ATRA) may be enhanced by myeloid growth factors, but the requirement for growth factors in this process is unclear. Our previous studies in m ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · January 2005
To evaluate high-dose therapy and autologous or allogeneic blood or marrow transplantation (BMT) for mantle cell lymphoma, patients receiving BMT for newly diagnosed or relapsed mantle cell lymphoma were identified through the registry at Johns Hopkins. Th ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · May 2003
Multiple myeloma may be cured by myeloablative conditioning and allogeneic blood or marrow transplantation (alloBMT), but this occurs at the expense of high transplant-related mortality. In an endeavor to reduce procedure-related toxicity, this study retro ...
Full textLink to itemCite
Journal articleJ Am Acad Dermatol · February 2001
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder. Less than 50 cases have been reported. We report the first case of CNL with an associated leukemia cutis. CNL was diagnosed in a 74-year-old white woman in 1998, based on neutrophil ...
Full textLink to itemCite
Journal articleBlood · July 1, 2000
To evaluate the response rate and potential toxicities, a phase II trial was conducted of fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated low-grade and select intermediate-grade lymphoid malignancies. Symptoma ...
Link to itemCite
Journal articleAnn Oncol · June 2000
BACKGROUND: Standard therapy for lymphoma consists of a cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P) (CHOP) combination regimen. Liposomal daunorubicin (DaunoXome) is an alternative to doxorubicin for patients with lymphoma becaus ...
Full textLink to itemCite
Journal articleAm J Kidney Dis · February 2000
Health maintenance includes secondary prevention through cancer screening. There are no established guidelines for cancer screening patients with end-stage renal disease (ESRD). Using an established method of estimating life expectancy, published literatur ...
Full textLink to itemCite
Journal articleCancer · December 15, 1999
BACKGROUND: The natural history of chronic lymphocytic leukemia (CLL) is changing, although the reasons (potential changes in the disease's biology or in patterns in patient characteristics, treatment, or referral) are unclear. METHODS: This report uses Na ...
Link to itemCite
Journal articleBr J Haematol · May 1999
We performed a prospective infectious natural history study of 21 patients with low-grade lymphoproliferative disorders receiving fludarabine as initial (n = 5) or salvage (n = 16) therapy. 12 (57%) of these patients developed herpes zoster (n = 9), herpes ...
Link to itemCite
Journal articleIntensive Care Med · February 1999
OBJECTIVE: To determine if D-dimer predicts outcomes in critically ill patients. DESIGN: Observational, cohort study. SETTING: Medical intensive care unit (MICU) of a tertiary care hospital. PATIENTS AND PARTICIPANTS: Seventy-four patients consecutively ad ...
Full textLink to itemCite
Journal articleBlood · November 15, 1998
Flavopiridol has been reported to induce apoptosis in lymphoid cell lines via downregulation of bcl-2. The in vitro activity of flavopiridol against human chronic lymphocytic leukemia (CLL) cells and potential mechanisms of action for inducing cytotoxicity ...
Link to itemCite
Journal articleJ Clin Oncol · May 1998
PURPOSE: A report of the clinical features, treatment, and outcome of patients who developed hemolytic anemia (HA) temporally associated with fludarabine (Fludara; Berlex Laboratories, Richmond, CA) therapy for chronic lymphocytic leukemia (CLL). PATIENTS ...
Full textLink to itemCite
Journal articleAnn Oncol · March 1998
BACKGROUND: The purpose of this study was to compare the long-term psychosocial adaptation of Hodgkin's disease and adult acute leukemia survivors. PATIENTS AND METHODS: Two hundred seventy-three Hodgkin's disease (HD) and 206 adult acute leukemia (AL) sur ...
Full textLink to itemCite
Journal articleAm J Med · February 1998
BACKGROUND: The effect of transfusion of small amounts of packed red blood cells (PRBC) on serum chemistry values is not known. METHODS: We studied 73 adult patients without evidence of bleeding who received 2-unit PRBC transfusions. In study 1 (n=39), we ...
Full textLink to itemCite
Journal articleSemin Oncol · February 1998
Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of adva ...
Link to itemCite
Journal articleMod Pathol · November 1997
Fludarabine is a highly effective chemotherapeutic agent for chronic lymphocytic leukemia/small lymphocytic lymphoma and is also active in other B-cell lymphoproliferative disorders. Although highly efficacious in destroying the malignant B-cells, fludarab ...
Link to itemCite
Journal articleThyroid · June 1997
Patients with Hodgkin's disease have higher a prevalence of thyroid function abnormalities and, perhaps, orbitopathy than the general population, but the pathophysiology of this association and its relationship to Hodgkin's disease treatment remain unclear ...
Full textLink to itemCite
Journal articleAm J Hematol · June 1995
The high incidence of opportunistic pulmonary infections in fludarabine-treated patients at Walter Reed Army Medical Center (WRAMC) and in the literature are described. A CancerLit search of fludarabine from June 1983-April 1994 with subsequent cross refer ...
Full textLink to itemCite
Journal articleAm J Hematol · October 1993
The measurement of the number of platelets larger than 3 microns (megathrombocyte index) is the first element in the evaluation of thrombocytopenia. This is currently performed by counting the number of large platelets on the peripheral blood film. The MPV ...
Full textLink to itemCite
Journal articleGastroenterol Clin North Am · December 1991
Patients with esophageal cancer present with a cancer that is locally aggressive in a critical area and that readily metastasizes. Neither surgery nor radiotherapy alone can control local disease, and chemotherapy alone cannot control local or disseminated ...
Link to itemCite
Journal articleInvest Radiol · December 1991
The presence of a large mediastinal mass (bulk disease) in patients with newly diagnosed Hodgkin disease is believed by many to predict a poorer prognosis and to warrant more aggressive treatment. These masses are formed by an aggregate of mediastinal lymp ...
Full textLink to itemCite
Journal articleArch Intern Med · March 1991
Hematologic profiles of 462 persons, mostly active-duty service members, were studied to determine whether hematologic differences between blacks and whites exist in a healthy population. Whites had significantly greater mean concentrations of leukocytes ( ...
Link to itemCite
Journal articleJ Clin Oncol · March 1991
Computed tomography (CT) was used to define the sites of intrathoracic abnormality in Hodgkin's disease, determine a pattern of progression of disease in the thorax, and establish the place of this pattern of spread in the differential diagnosis of thoraci ...
Full textLink to itemCite
Journal articleAJR Am J Roentgenol · August 1990
Necrosis in lymph nodes shown on CT in many patients with nodal metastases may indicate that the primary tumor is aggressive and has a high degree of malignancy. However, the significance of nodal necrosis in patients with mediastinal Hodgkin disease remai ...
Full textLink to itemCite
Journal articleMed Pediatr Oncol · 1990
The size of the mediastinal mass on standard posterior-anterior chest radiograph in stage I and stage II Hodgkin's disease has both prognostic and therapeutic importance. But the actual treatment is based on the anterior-posterior supine simulation film. P ...
Full textLink to itemCite
Journal articleAm J Hematol · March 1989
The purpose of this study was to test the value of the Ann Arbor staging procedures committee criteria in defining a group of newly diagnosed patients with Hodgkin disease who do not have involvement of the bone marrow and do not need this procedure perfor ...
Full textLink to itemCite
Journal articleJ Gen Intern Med · 1989
Sixty-five physicians were tested to determine the effect of their reviews of red blood cell morphology on their subsequent diagnoses of and workup plans for common anemias. The subjects read clinical and laboratory data for six pairs of cases of anemia, r ...
Full textLink to itemCite
Journal articleRadiology · October 1988
One hundred seven consecutive new cases of Hodgkin disease were evaluated with chest radiography and computed tomography (CT) for initial staging. The data were evaluated with regard to five popular treatment protocols for Hodgkin disease. Thoracic CT scan ...
Full textLink to itemCite
Journal articleArch Androl · 1988
To assess whether oligospermia in infertile men might be associated with abnormalities of another rapidly dividing cell population, namely, blood cells, we studied retrospectively hematologic indexes in 72 unselected men initially attending an infertility ...
Full textLink to itemCite
Journal articleCancer Chemother Pharmacol · 1988
A case of fatal dilated cardiomyopathy induced by esorubicin (ESO) at a total dose of 740 mg/m2, given in 27 doses over 650 days, is reported. The sudden onset, rapid clinical deterioration, and fatal outcome are detailed. The outcome was not predicted by ...
Full textLink to itemCite
Journal articleJ Clin Oncol · July 1986
The use of a historical control group is predicated on the assumption that survival and relapse-free survival in the historical control group closely approximate the survival and relapse-free survival in a randomized concurrent control group. This assumpti ...
Full textLink to itemCite
Journal articleCancer · May 1, 1984
Two cases of tumor recurrence within a previously irradiated skin area are reported. Typical lesions evolve from an erythematous base and progress to induration and tumor papules. A review of clinical literature indicates that irradiation does not increase ...
Full textLink to itemCite
Journal articleDrug Intell Clin Pharm · February 1984
A case is presented that describes the use of an intravenous morphine infusion to treat severe pain in an outpatient setting. The patient had severe pain secondary to tumor involvement of the brachial plexus. Morphine was administered as a concentrated sol ...
Full textLink to itemCite
Journal articleCancer Treat Rep · September 1983
Six patients with Hodgkin's disease who failed MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy, with recurrences confined to lymph node areas, are reported. All patients were treated with tumoricidal doses of irradiation in m ...
Link to itemCite
Journal articleCancer · August 1, 1982
A 29-year-old male developed myasthenia gravis 29 months after resection of a "benign" mediastinal thymoma. Metastatic thymoma was found in the pleura 45 months after the initial surgical resection. Combination chemotherapy with cyclophosphamide and doxoru ...
Full textLink to itemCite
Journal articleBlood · June 1982
Structural membrane proteins were studied from erythrocytes (RBC) of a patient with a nonhemolytic form of hereditary elliptocytosis (HE) who developed a microcytic anemia with fragmented RBC while cobalamin (B12) deficient. Evidence is presented for quali ...
Link to itemCite
Journal articleBlood · January 1982
We report a patient with a disease characterized by proliferation of T cells with Fc receptors for IgG (TG). However, unlike lymphoid cells from normal individuals or from patients with other lymphoid malignancies, the patient's lymphocytes spontaneously p ...
Link to itemCite